Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.

Autor: Berg JL; Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria., Perfler B; Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria., Hatzl S; Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria., Mayer MC; Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria., Wurm S; Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria., Uhl B; Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria., Reinisch A; Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria., Klymiuk I; Core Facility Molecular Biology, Medical University of Graz, Graz, Austria., Tierling S; Department of Genetics, University of Saarland, Saarbrücken, Germany., Pregartner G; Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria., Bachmaier G; Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria., Berghold A; Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria., Geissler K; 5th Medical Department with Hematology, Oncology and Palliative Medicine, Hospital Hietzing, Vienna, Austria.; Sigmund Freud University, Vienna, Austria., Pichler M; Division of Oncology, Medical University of Graz, Graz, Austria.; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Centre, Houston, TX, USA., Hoefler G; Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria., Strobl H; Otto Loewi Research Centre, Immunology and Pathophysiology, Medical University of Graz, Graz, Austria., Wölfler A; Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria., Sill H; Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria., Zebisch A; Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria. armin.zebisch@medunigraz.at.; Otto-Loewi Research Centre for Vascular Biology, Immunology and Inflammation, Division of Pharmacology, Medical University of Graz, Universitätsplatz 4, 8010, Graz, Austria. armin.zebisch@medunigraz.at.
Jazyk: angličtina
Zdroj: Clinical epigenetics [Clin Epigenetics] 2021 Jan 06; Vol. 13 (1), pp. 1. Date of Electronic Publication: 2021 Jan 06.
DOI: 10.1186/s13148-020-00979-2
Abstrakt: Background: Chronic myelomonocytic leukemia (CMML) is an aggressive hematopoietic malignancy that arises from hematopoietic stem and progenitor cells (HSPCs). Patients with CMML are frequently treated with epigenetic therapeutic approaches, in particular the hypomethylating agents (HMAs), azacitidine (Aza) and decitabine (Dec). Although HMAs are believed to mediate their efficacy via re-expression of hypermethylated tumor suppressors, knowledge about relevant HMA targets is scarce. As silencing of tumor-suppressive micro-RNAs (miRs) by promoter hypermethylation is a crucial step in malignant transformation, we asked for a role of miRs in HMA efficacy in CMML.
Results: Initially, we performed genome-wide miR-expression profiling in a Kras G12D -induced CMML mouse model. Selected candidates with prominently decreased expression were validated by qPCR in CMML mice and human CMML patients. These experiments revealed the consistent decrease in miR-125a, a miR with previously described tumor-suppressive function in myeloid neoplasias. Furthermore, we show that miR-125a downregulation is caused by hypermethylation of its upstream region and can be reversed by HMA treatment. By employing both lentiviral and CRISPR/Cas9-based miR-125a modification, we demonstrate that HMA-induced miR-125a upregulation indeed contributes to mediating the anti-leukemic effects of these drugs. These data were validated in a clinical context, as miR-125a expression increased after HMA treatment in CMML patients, a phenomenon that was particularly pronounced in cases showing clinical response to these drugs.
Conclusions: Taken together, we report decreased expression of miR-125a in CMML and delineate its relevance as mediator of HMA efficacy within this neoplasia.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje